Fake News and Murder Charges: How Italy Became Ground Zero for AstraZeneca’s Disastrous Rollout - Yahoo News Canada | Canada News Media
Connect with us

Business

Fake News and Murder Charges: How Italy Became Ground Zero for AstraZeneca’s Disastrous Rollout – Yahoo News Canada

Published

 on


Massimo Pinca via Reuters

ROME—Nothing kills faith in a vaccine quite like manslaughter charges implying that it’s lethal. It helps little when the same drugmaker is accused of fudging data and hiding millions of vials in a warehouse inside Italy—a country experiencing massive vaccine shortages.

The Oxford-AstraZeneca COVID-19 Vaccine Was Paused. That’s a Good Thing.

But such is the story of AstraZeneca’s COVID-19 vaccine curse. Once hoped to be the workhorse of the European Union’s vaccine program, the AstraZeneca vaccine was meant to offer an escape route out of the pandemic But now people are rolling their sleeves back down at the thought of getting an AZ jab.

But for all the bad press, little of it is actually true.

News reports Wednesday morning out of Italy screamed that the company had hidden or lost 30 million doses in a warehouse south of Rome—around the same number of doses they failed to deliver to the continent thanks to what they had, at the time, called production glitches.

But the 30 million doses in the Catalent finishing facility that La Stampa newspaper claimed were lost were actually well-documented and inventoried, a representative for Catalent told The Daily Beast.

They all had lot numbers and none were ever intended for Europe. Instead, most were prepared to be sent to third-world countries as part of the Covax agreement. A small number of the vials were destined for the U.K., which would likely be blocked by a European Union ban on exports of vaccines made in Europe (and a precedent set by Italy earlier this month when the country banned AstraZeneca exports to Australia). And the rest are earmarked for the European Union, according to AstraZeneca. But the doses were not “found” because, in fact, they had never been “lost.”

AstraZeneca also issued a statement meant to clarify its distribution. “There are no exports currently planned other than to COVAX countries,” the statement said. “It is incorrect to describe this as a stockpile. The process of manufacturing vaccines is very complex and time consuming. In particular, vaccine doses must wait for quality control clearance after the filling of vials is completed.”

Whether those doses should or should not be distributed in Europe is an entirely different question and one no one The Daily Beast contacted seemed to be able to answer. “There are protocols to follow on the distribution of these vaccines,” Antonio Addis, head of the Dept. of Epidemiology in Rome’s First Municipal Medical district says. “You cannot just go into a warehouse and take the vials intended for someone else because you are running short.”

But missing doses are not AstraZeneca’s only woes. The vaccine hit another glitch this week when American drug regulators publicly questioned whether the company had supplied outdated data on the trials under consideration. A midnight missive Sunday came after the British-Swedish drug maker released a press release over the weekend touting a level of effectiveness that it claimed paved the way to FDA approval. Both sides now say they are updating data and that the vaccine is still on target to be approved for use in the U.S. in April.

But the most devastating hit has been lingering doubt about whether the jab causes sometimes-fatal blood clots, which led to a manslaughter investigation into two doctors and a nurse who injected someone who later died in Italy. Last week, after a dozen countries suspended the vaccine’s use, the European drug regulator deemed it safe but insisted labeling should be updated to hint that some people may experience clotting. Most countries brought the vaccine back online, but notably Sweden—one of AstraZeneca’s home countries—did not.

The Italian manslaughter case is still ongoing after a Sicilian prosecutor ordered the sequester—by SWAT team no less—of thousands of vials on March 11. When the manslaughter suit was launched, the head of the World Medical Association, which represents doctors from 115 countries, said the damage from the investigation would be devastating. “In any other country in the European Union, this would not be considered manslaughter,” Frank Montgomery, the World Medical Association’s chairperson, told Reuters. “Possible side-effects from a vaccination would never lead to the prosecution of a doctor.”

Italy’s legal system allows for manslaughter investigations to be easily launched when someone dies, in part to secure transparency to all evidence collected in a wrongful death investigation. The most famous case came after an earthquake in L’Aquila in 2006 led to the conviction and then acquittal of scientists who told local residents not to worry about increased seismic activity and “go home and have a glass of wine” instead. When a deadly quake struck and killed hundreds, the seismologists and scientists were arrested and tried for murder. In the case of the earthquake, the scientists were eventually acquitted on appeal, but the damage done to confidence in the scientific community has yet to be rebuilt.

The same is likely the case for AstraZeneca, which continues to feel the aftershocks of its less than stable rollout.

Read more at The Daily Beast.

Get our top stories in your inbox every day. Sign up now!

Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version